- Home
- YQ vs CLRB Comparison
YQ vs CLRB Comparison
Compare YQ & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | CLRB |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 12.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YQ | CLRB |
|---|---|---|
| Price | $3.35 | $3.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 146.9K |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,563,434.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $2.45 |
| 52 Week High | $6.45 | $20.60 |
Technical Indicators
Market Signals| Indicator | YQ | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 55.15 |
| Support Level | $3.22 | $3.50 |
| Resistance Level | $3.59 | $4.10 |
| Average True Range (ATR) | 0.23 | 0.34 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 48.57 | 69.18 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.